Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

The changing landscape of biosimilars in rheumatology

(2016) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases

(2016) Stefano Gentileschi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn’s and Ulcerative Colitis Associations: Table 1.

(2016) Laurent Peyrin-Biroulet et al.   Journal of Crohns & Colitis

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study

(2016) Lisa J. T. Smits et al.   Journal of Crohns & Colitis

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data

(2015) Elena Nikiphorou et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab

(2013) M Neovius et al.   ANNALS OF THE RHEUMATIC DISEASES

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays

(2012) N. Vande Casteele et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Nocebo Effect and Its Relevance for Clinical Practice

(2011) Luana Colloca et al.   PSYCHOSOMATIC MEDICINE

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

(2009) Merete Lund Hetland et al.   ARTHRITIS AND RHEUMATISM